USPSTF: Evidence Lacking for Lipid Disorder Screening in Children
Current evidence is inadequate for assessing the balance of benefits and harms of screening in a pediatric population
Current evidence is inadequate for assessing the balance of benefits and harms of screening in a pediatric population
The APH-19 trial enrolled a total of 46 patients 5 to 17 years of age with HoFH who had a mean LDL-C at baseline of 436 mg/dL.
Risk reduced for lobar and nonlobar intracerebral hemorrhage; greater reductions seen with prolonged use ≥5 years
Clinician nudge alone or in combination with a patient nudge increases initiation of statin prescribing versus usual care
Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3.
The study included adults aged 40 to 75 years with no history of cardiovascular disease, an LDL-C of 70-189 mg/dL, and a 5-20% 10-year risk of ASCVD.
Only one of 15 muscle symptom-related reports by study participants assigned to statins believed to be due to statins
Expert consensus decision pathway developed for patients currently taking statins and needing additional treatment
Findings showed that treatment with evolocumab resulted in clinically significant and sustained reduction in LDL-C levels.
These recommendations apply only to individuals without a history of CVD and who are not already taking statins.